Using bioimpedance analysis to assess risks in lung surgery
Bioimpedance Analysis in Perioperative Assessment in Thoracic Surgery
NA · Azienda USL Reggio Emilia - IRCCS · NCT06796816
This study tests if a method that measures body composition can help doctors identify patients at higher risk for complications before lung surgery for adenocarcinoma.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Azienda USL Reggio Emilia - IRCCS (other gov) |
| Locations | 1 site (Reggio Emilia) |
| Trial ID | NCT06796816 on ClinicalTrials.gov |
What this trial studies
This study evaluates the use of bioelectrical impedance vector analysis (BIVA) to assess surgical and postoperative risks in patients undergoing lung resection for adenocarcinoma. By analyzing body composition, particularly muscle mass and hydration status, the study aims to improve prognostic assessments and better understand individual responses to surgery. The goal is to identify patients at higher risk for complications based on their physiological status prior to surgery.
Who should consider this trial
Good fit: Ideal candidates are patients scheduled for pulmonary resection surgery for primary lung neoplasms within the past year.
Not a fit: Patients with chronic atrial fibrillation, prior major pulmonary resections, or those with pacemakers may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized surgical care and improved outcomes for lung cancer patients.
How similar studies have performed: Other studies utilizing bioimpedance analysis for prognostic assessments in oncology have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients undergoing pulmonary resection surgery for primary neoplasm within a one-year timeframe. Exclusion Criteria: * Patients with chronic atrial fibrillation (AF). * Patients who have previously undergone major pulmonary resection. * Patients with pacemakers or implantable devices, as the use of bioimpedance vector analysis (BIVA) may be contraindicated.
Where this trial is running
Reggio Emilia
- AUSL IRCCS di Reggio Emilia — Reggio Emilia, Italy (RECRUITING)
Study contacts
- Study coordinator: Cristian Rapicetta, MD
- Email: Cristian.rapicetta@ausl.re.it
- Phone: 0522296858
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Resection, Adenocarcinoma of Lung, bioimpedence, lung cancer, sarcopenia